Pembrolizumab, an immune control point inhibitor, has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with amputation locally advanced carcinoma carcinoma of head and throats whose tumors express PD-L1 tumors [Combined Positive Score (CPS) ≥1] as specified by a test approved by the FDA.
The approval of the FDA is based on data from the Pivotal Keynote-689 study, a randomized, open phase 3 clinical trial in which patients receiving pembrolizumab before, during and after standard surgery, had more survival without events without cancer and higher cancer. The study was driven by researchers by Dana-Farber Brigham Cancer Center and the University of Washington Medical School in St. Louis.
This new shape represents a substantial change in the workflow for head cancer and neck care, offering appropriate patients to take pembrolizumab reception before surgery to suspend local advanced head and neck cancer.
These findings represent a truly exciting moment for our patients, as it is the first progress in this area in over two decades. ”
Dr. Ravindra Uppaluri, the overall major researcher of the study, director of the head and neck surgical oncology at Dana-Farber and Brigham and women’s hospital as
“This is the first approval of a checkpoint inhibitor in the therapeutic, perioperative environment and represents a huge shift of the example to the way we manage surgery at Harvard Cancer and Neck Medical,” said Dr. Robert Haddad, head of Head and Camper Oncology and McGraw’s chair at Head and Neck Oncology in Dana-Farber. of Keynote-689 Management Committee.
The Keynote-689 test was randomized 714 patients with a newly-known stage 3 or stage 4A cancer and the squamous cell to receive either pembrolizumab before (called neoadjuvant), during and after (called immunoso-nodal) pattern or template. The researchers also measured the presence of the target of Pembrolizumab, PD-L1, in tumors to determine if higher PD-L1 ratings would affect the response to treatment.
The study met with its main end point, showing that patients who received pembrolizumab had more survival without events. The average survival without incidents was 51.8 months with pembrolizumab and 30.4 without a 38.3 -month median medication. The group also observed significantly higher rates of major pathological reaction, a significant tumor destruction caused by an immune tumor observed in surgical resection.
The treatment was found to be safe without new observed side effects. Furthermore, patients receiving pembrolizumab received surgery in time and did not delay from side effects associated with immunotherapy before surgery.
The data was previously presented at the annual meeting of the American Cancer Association (AACR) of 2025.
Source:
